[{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Avecho","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2025","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avecho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avecho \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Avecho \/ Sandoz B2B"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"||Adenosine A2 receptor | 3\\',5\\'-cyclic phosphodiesterase","graph1":"Oncology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University Health Network, Toronto \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ AstraZeneca"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"||Adenosine A2 receptor | 3\\',5\\'-cyclic phosphodiesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Inapplicable"},{"orgOrder":0,"company":"Yuen Kah Hay","sponsor":"Monash University Malaysia | Hovid BHD","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tocotrienol","moa":"||Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Yuen Kah Hay","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuen Kah Hay \/ Monash University Malaysia | Hovid BHD","highestDevelopmentStatusID":"8","companyTruncated":"Yuen Kah Hay \/ Monash University Malaysia | Hovid BHD"},{"orgOrder":0,"company":"Irma Bernadette","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Kojic Acid","moa":"||Tyrosinase (TYR)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Irma Bernadette","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Irma Bernadette \/ Menarini","highestDevelopmentStatusID":"1","companyTruncated":"Irma Bernadette \/ Menarini"},{"orgOrder":0,"company":"Pharmanex","sponsor":"Clinical Research Australia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Astaxanthin Grape Extract","moa":"||Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Pharmanex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanex \/ Clinical Research Australia","highestDevelopmentStatusID":"1","companyTruncated":"Pharmanex \/ Clinical Research Australia"}]

Find Clinical Drug Pipeline Developments & Deals for Tocopheryl Acid Succinate, d-Alpha

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the agreement, Sandoz gains the commercial rights to Avecho's Phase III cannabidiol (CBD) capsule for insomnia in Australia.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : $3.0 million

                          March 03, 2025

                          Lead Product(s) : Cannabidiol,Vitamin E

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase III

                          Sponsor : Sandoz B2B

                          Deal Size : $19.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist (Testosterone Undecanoate) and α-tocopherol, an antioxidant, is being investigated for the treament of obesity.

                          Product Name : Tlando

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          November 04, 2024

                          Lead Product(s) : Testosterone Undecanoate,Vitamin E

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University Health Network, Toronto

                          Country arrow
                          EPSC
                          Not Confirmed

                          University Health Network, Toronto

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 09, 2024

                          Lead Product(s) : Pentoxifylline,Vitamin E

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Irma Bernadette

                          Country arrow
                          EPSC
                          Not Confirmed

                          Irma Bernadette

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 18, 2023

                          Lead Product(s) : Kojic Acid,Vitamin E,Vitamin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Sponsor : Menarini

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          September 29, 2023

                          Lead Product(s) : Coenzyme Q10,Vitamin E

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          06

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 26, 2023

                          Lead Product(s) : Pentoxifylline,Vitamin E,Clodronic Acid Disodium Salt

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Qunol

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          July 27, 2023

                          Lead Product(s) : Coenzyme Q10,Vitamin E

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          08

                          Pharmanex

                          Country arrow
                          EPSC
                          Not Confirmed

                          Pharmanex

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          July 12, 2023

                          Lead Product(s) : Astaxanthin Grape Extract,Vitamin E

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Clinical Research Australia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Yuen Kah Hay

                          Country arrow
                          EPSC
                          Not Confirmed

                          Yuen Kah Hay

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 11, 2021

                          Lead Product(s) : Tocotrienol,Vitamin E

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Monash University Malaysia | Hovid BHD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Naga P. Chalasani

                          Country arrow
                          EPSC
                          Not Confirmed

                          Naga P. Chalasani

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          December 13, 2019

                          Lead Product(s) : Vitamin E,Omega-3

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Royal DSM

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank